500420 Share Price Performance
₹3,718.20
450.20 (13.78%)
7.3% undervalued intrinsic discount
₹4,010.04
Fair Value
Price ₹3,718.20
AnalystConsensusTarget ₹4,010.04
Fair Value₹4,010.04
Share Pricen/a
Torrent Pharmaceuticals Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
500420 Community Narratives
AN
Fair Value ₹4.01k 7.3% undervalued intrinsic discount
Robust Indian And Brazilian Markets Will Unlock Potential
1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Robust Indian And Brazilian Markets Will Unlock Potential
Key Takeaways Sustained branded market growth, strategic launches, and chronic disease focus are driving higher demand, market share, and improved earnings outlook. Expanding product pipelines, R&D investments, and broadening global presence support long-term revenue growth and margin enhancement.Read more
1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
₹4.01k
7.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
12.37% p.a.
Profit Margin
22.79%
Future PE
49.06x
Share price in 2028
₹5.74k
Recently Updated Narratives
AN
Robust Indian And Brazilian Markets Will Unlock Potential
Fair Value: ₹4.01k 7.3% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Outstanding track record with flawless balance sheet and pays a dividend.
1 Risk
2 Rewards
Torrent Pharmaceuticals Limited Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 63.24
- 75.69%
- 17.47%
- 30.7%
About 500420
- Founded
- 1959
- Employees
- 17059
- CEO
- WebsiteView website
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited.
